(Q38102879)

28 August 2017

title

DNA methylation-based biomarkers in bladder cancer (English)

1 reference

28 August 2017

0 references

0 references

Raju Kandimalla

1

0 references

author name string

Angela A van Tilborg

series ordinal

2

1 reference

28 August 2017

Ellen C Zwarthoff

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

30 April 2013

1 reference

28 August 2017

published in

Nature Reviews Urology

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

6

1 reference

28 August 2017

page(s)

327-335

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2013.89

28 August 2017

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Factors affecting recurrence and progression in superficial bladder tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Bladder cancer subtypes defined by genomic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Hypermethylation in bladder cancer: biological pathways and translational applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

The power and the promise of DNA methylation markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Epigenetic gene silencing in cancer: the DNA hypermethylome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

The Polycomb group protein EZH2 directly controls DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

A DNA methylation fingerprint of 1628 human samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Carcinogen exposure and gene promoter hypermethylation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Low frequency of epigenetic events in urothelial tumors in young patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Promoter hypermethylation identifies progression risk in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Discovery of myopodin methylation in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Identification of PMF1 methylation in association with bladder cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Identification of methylated genes associated with aggressive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Urine markers for bladder cancer surveillance: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Statistical consideration for clinical biomarker research in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Evaluating markers for the early detection of cancer: overview of study designs and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Multiplexed methylation profiles of tumor suppressor genes in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Global epigenetic profiling in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

The FGFR3 mutation is related to favorable pT1 bladder cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Epigenetic Inactivation of SFRP Genes and TP53 Alteration Act Jointly as Markers of Invasive Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Myopodin Methylation is Associated With Clinical Outcome in Patients With T1G3 Bladder Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2013.89

Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients

31 March 2020

1 reference

12 December 2020

FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder

1 reference

12 December 2020

Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features

1 reference

12 December 2020

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2013.89

1 reference

Dimensions Publication ID

28 August 2017

1021047654

0 references

1 reference